Fig. 1From: Cardiovascular and mortality benefits of sodium–glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real CataloniaIncidence rates of the different events per 100 person-years by treatment. CKD chronic kidney disease, HF heart failure, MACE major adverse cardiovascular events, MI myocardial infarction, oGLDs other glucose-lowering drugs, PY patient-years of exposure, SGLT2i sodium–glucose co-transporter inhibitorsBack to article page